|

Bundle Branch Pacing to Preserve Ejection Fraction in Atrial Fibrillation Trial

RECRUITINGN/ASponsored by Poitiers University Hospital
Actively Recruiting
PhaseN/A
SponsorPoitiers University Hospital
Started2026-10-15
Est. completion2028-10-14
Eligibility
Age18 Years – 90 Years
Healthy vol.Accepted

Summary

The goal of this clinical trial is to learn whether left bundle branch area pacing, a technique designed to activate the heart's natural electrical conduction system, is better than conventional right ventricular pacing in adults with permanent atrial fibrillation, preserved heart pumping function, and a need for a pacemaker. The main questions it aims to answer are: Does left bundle branch area pacing reduce the risk of death, unplanned hospitalization for heart failure, or the need to replace the initial pacing system with biventricular pacing over 2 years? Does it better preserve heart function and quality of life, without increasing pacemaker-related complications? Researchers will compare left bundle branch area pacing with conventional right ventricular pacing. A total of 642 participants will be randomly assigned to receive one of these two pacing strategies. Participants will: Have a single-chamber pacemaker implanted using either left bundle branch area pacing or conventional right ventricular pacing Undergo electrocardiograms, echocardiograms, and pacemaker checks during 2 years of follow-up Attend follow-up visits approximately 2, 12, and 24 months after implantation Be contacted by telephone approximately 6 and 18 months after implantation Complete questionnaires about their health and quality of life at the beginning and end of the study

Eligibility

Age: 18 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age ≥ 18 years and \<90 years
* Atrial fibrillation requiring ventricular pacing because of

  1. rapid atrial fibrillation requiring atrioventricular node ablation; or
  2. slow atrial fibrillation i.e. ≤ 50 bpm on admission ECG).
* Left ventricular ejection fraction ≥50%.
* Affiliated person or beneficiary of the French social security scheme
* Having given their informed consent.

Exclusion Criteria:

* Indication for an implantable cardioverter defibrillator.
* Presence of a mechanical tricuspid valve
* Any prior attempt at implantation of an implantable cardioverter defibrillator, cardiac resynchronization therapy or LBBA pacing
* Glomerular filtration rate \<40 mL/min/1,73m2 with CKD-EPI formula
* Chronic respiratory failure
* Serious medical condition with life expectancy of \<2 years
* Pregnant or breastfeeding women, women of childbearing age who do not have effective contraception (hormonal/mechanical: per os, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy)
* Persons benefiting from enhanced protection, i.e. minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social institution, adults under legal protection, and finally patients in emergency situations

Conditions3

Heart DiseasePermanent Atrial FibrillationPreserved Ejection Fraction

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.